Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06405217
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-04-29
Brief Title:
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Sponsor:
Nanjing First Hospital Nanjing Medical University
Organization:
Nanjing First Hospital Nanjing Medical University
Study Overview
Official Title:
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment in Patients With Locally AdvancedMetastatic Differentiated Thyroid Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Subjects patients with postoperative local recurrent or metastatic differentiated thyroid cancer
Experimental group Recombinant human thyroid stimulating hormone injection 09mg10mLpiece intramuscular injection once a day for two consecutive days Control group Thyroid hormone withdraw for 4-6 weeks
The two groups were treated with radioiodine 131I after plasma thyroid stimulating hormone elevated 30mUL The efficacy and adverse reactions were observed
Experimental group Recombinant human thyroid stimulating hormone injection 09mg10mLpiece intramuscular injection once a day for two consecutive days Control group Thyroid hormone withdraw for 4-6 weeks
The two groups were treated with radioiodine 131I after plasma thyroid stimulating hormone elevated 30mUL The efficacy and adverse reactions were observed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None